A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma

Inclusion Criteria

• •Aged 18 years or older at the time of consent.
• •History of airflow obstruction as indicated by a pre-bronchodilator forced expiratory volume in one second (FEV1) \<80 percent predicted recorded in the previous 12 months.
• •Documented evidence of a reversibility assessment within the previous 12 months, which demonstrated a post-bronchodilator increase in FEV1 of \>=12 percent and \>= 200 milliliters (mL).
• •Diagnosed with moderate or severe asthma as defined by a stable maintenance inhaled corticosteroid (ICS) dose for at least 12 weeks prior to screening of; moderate: medium ICS dose \> 250 and \<=500 micrograms per day (mcg/day) fluticasone propionate (or equivalent) based on the total daily maintenance treatment dose; Severe: high ICS dose \> 500 mcg/day fluticasone propionate (or equivalent) based on the total daily maintenance treatment dose.
• •Documented control status defined using the asthma control questionnaire (ACQ-6) items (ACQ-6) obtained at the time of screening.
• •Able to understand, read and speak English or Spanish sufficiently to complete all assessments.
• •Willing and able to take part in a telephone interview session.
• •Willing and able to provide written informed consent.